newsfilter
← Latest News
Business Wire·

Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report

Achieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company's gene therapy candidate being developed to treat a specific form of congenital